Literature DB >> 16444446

Recombinant activated factor VII combined with desmopressin in preventing bleeding from dental extraction in a patient with Glanzmann's thrombasthenia.

Vincenzo Trapani Lombardo1, Gianluca Sottilotta.   

Abstract

The case of a 41-year-old woman with Glanzmann's thrombasthenia who underwent double dental extraction is presented. In the past, treatments with desmopressin (DDAVP) and tranexamic acid had often unsuccessful efficacy to stop or decrease bleeding. After ineffective DDAVP administration, the removal was performed successfully with recombinant activated factor VII (rFVIIa) infusion. rFVIIa infusion after DDAVP administration could be useful in patients with Glanzmann's thrombasthenia in which DDAVP and tranexamic acid weren't always effective.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16444446     DOI: 10.1177/107602960601200120

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  3 in total

Review 1.  Glanzmann Thrombasthenia: Perspectives from Clinical Practice on Accurate Diagnosis and Optimal Treatment Strategies.

Authors:  Natalie Mathews; Georges-Etienne Rivard; Arnaud Bonnefoy
Journal:  J Blood Med       Date:  2021-06-11

Review 2.  Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.

Authors:  Man-Chiu Poon
Journal:  Vasc Health Risk Manag       Date:  2007

3.  Glanzmann's Thrombastenia: The Role of Tranexamic Acid in Oral Surgery.

Authors:  Rocco Franco; Michele Miranda; Laura Di Renzo; Antonino De Lorenzo; Alberta Barlattani; Patrizio Bollero
Journal:  Case Rep Dent       Date:  2018-09-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.